About

About GlyTech, Inc. GlyTech, Inc. uses advanced peptide discovery, brain delivery, and cell-free glycosylation technologies based on nature-derived structures to develop next-generation biotherapeutics and support ADC and biologics R&D. Our capabilities span all drug development stages from discovery to commercialization. 1. Our nose-to-brain delivery technology transports therapeutic compounds via a novel pathway that bypasses the BBB. 2. Our cell-free, glycan reagent-based glyco-optimization platform allows us to modify the physicochemical properties of lead compounds with full control of glycan structure, number and position. The most advanced candidate within our pipeline, a glycan-modified hormone, has now completed P2a clinical trial. 3. Our human type glycans, which can be used for drug development as highly biocompatible linkers for ADCs, PDCs, or other biotherapeutics, are available from the milligram to multi-kilogram scale. 4. Our highly efficient target-based peptide discovery platform produces leads with promising drug-like properties and high development potential within a shorter time span.